Bank of Nova Scotia
MRNA icon

Bank of Nova Scotia’s Moderna MRNA Stock Holding History

Bank of Nova Scotia’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Sell
7,735
-48
-0.6% -$2.48K ﹤0.01% 932
2026
Q1 		$395K Sell
7,783
-56,563
-88% -$2.64M ﹤0.01% 950
2025
Q4 		$1.9M Buy
64,346
+31,863
+98% +$866K ﹤0.01% 790
2025
Q3 		$839K Sell
32,483
-1,299
-4% -$36.2K ﹤0.01% 813
2025
Q2 		$932K Buy
33,782
+21,280
+170% +$560K ﹤0.01% 780
2025
Q1 		$354K Sell
12,502
-28,403
-69% -$1.01M ﹤0.01% 849
2024
Q4 		$1.7M Buy
40,905
+1,430
+4% +$68.3K ﹤0.01% 713
2024
Q3 		$2.64M Buy
39,475
+9,834
+33% +$903K 0.01% 600
2024
Q2 		$3.52M Sell
29,641
-2,113
-7% -$267K 0.01% 529
2024
Q1 		$3.38M Sell
31,754
-14,046
-31% -$1.42M 0.01% 567
2023
Q4 		$4.55M Buy
45,800
+18,574
+68% +$1.56M 0.01% 518
2023
Q3 		$2.81M Buy
27,226
+6,000
+28% +$669K 0.01% 514
2023
Q2 		$2.58M Buy
21,226
+8,644
+69% +$1.15M 0.01% 478
2023
Q1 		$1.93M Sell
12,582
-72,170
-85% -$11.9M 0.01% 553
2022
Q4 		$15.2M Sell
84,752
-72,046
-46% -$11.8M 0.04% 278
2022
Q3 		$18.5M Sell
156,798
-13,465
-8% -$2.04M 0.06% 232
2022
Q2 		$24.3M Sell
170,263
-23,968
-12% -$3.43M 0.06% 245
2022
Q1 		$33.5M Sell
194,231
-48,699
-20% -$8.2M 0.06% 270
2021
Q4 		$61.8M Buy
242,930
+135,395
+126% +$39.6M 0.09% 209
2021
Q3 		$41.4M Sell
107,535
-42,573
-28% -$15.7M 0.07% 236
2021
Q2 		$35.3M Buy
150,108
+146,747
+4,366% +$26.2M 0.07% 232
2021
Q1 		$440K Sell
3,361
-2,430
-42% -$352K ﹤0.01% 967
2020
Q4 		$605K Sell
5,791
-2,355
-29% -$238K ﹤0.01% 854
2020
Q3 		$576K Buy
8,146
+1
+0% +$70 ﹤0.01% 839
2020
Q2 		$523K Buy
+8,145
New +$446K ﹤0.01% 736

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Bank of Nova Scotia's MRNA Position: Q2 2026 in Review

Bank of Nova Scotia reduced its Moderna (MRNA) stake by 0.62% in Q2 2026, selling an estimated $2.48K and leaving 7,735 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #932.

Bank of Nova Scotia first reported a position in MRNA in Q2 2020 and has held it in 25 quarters since. The position peaked at $61.8M in Q4 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Bank of Nova Scotia held 7,735 shares of Moderna worth $542K as of Q2 2026.
  • Bank of Nova Scotia sold 48 Moderna shares in Q2 2026, an estimated $2.48K.
  • Moderna made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q2 2026, its #932 holding.
  • Bank of Nova Scotia first reported a position in Moderna in Q2 2020 and has held it in 25 quarters since.
  • Bank of Nova Scotia's Moderna position peaked at $61.8M in Q4 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Bank of Nova Scotia's 13F filing for Q2 2026, filed 12 Aug 2026.